Protective effect of sodium butyrate on the cell culture model of Huntington disease

references

• Nance , M A . 1998 . Huntington disease: clinical, genetic and social aspects . J Geriatr Psychatry Neurol , 11 : 11 – 70 .
   Google Scholar
• Petersen , A , Mani , K and Brundin , P . 1999 . Recent advances on the pathogenesis of Huntington disease . Exp Neurol , 157 : 1 – 6 .
   PubMed Web of Science ®Google Scholar
• The Huntington's Disease Collaborative Research Group . 1993 . A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes . Cell , 72 : 971 – 983 .
   PubMed Web of Science ®Google Scholar
• Perz-Navarro , E , Canals , J M and Gines , S . 2006 . Cellular molecular mechanisms involved in the selective vulnerability of striatal projection neurons in Huntington's disease . Histol Histopathol , 21 ( 11 ) : 1217 – 1232 .
   Google Scholar
• Sadri-Vakili , G and Cha , J H . 2006 . Mechanisms of disease: Histone modifications in Huntington's disease . Nat Clin Pract Neurol , 2 ( 6 ) : 330 – 338 .
   PubMedGoogle Scholar
• Fryer , D J and Zoghbi , Y H . 2006 . Huntingtin's critical cleavage . Nat Neurosci , 9 ( 9 ) : 1088 – 1089 .
   Google Scholar
• Wellington , C L , Ellerby , L M Gutekunst , C A . 2002 . Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease . J Neurosci , 22 ( 18 ) : 7862 – 7872 .
   Google Scholar
• Gafni , J , Hermel , E Young , J E . 2004 . Inhibition of calpain cleavage of huntingtin reduces toxicity: accumulation of calpain/caspase fragments in the nucleus . J Biol Chem , 279 ( 19 ) : 2011 – 20220 .
   Google Scholar
• Lunkes , A , Lindenberg , K S Ben-Haiem , L . 2002 . Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions . Mol Cell , 10 ( 2 ) : 224 – 225 .
   Google Scholar
• Sugars , K L and Rubinsztein , D C . 2003 . Transciptional abnormalities in Huntington disease . Trends Genet , 19 : 233 – 238 .
   PubMed Web of Science ®Google Scholar
• Monneret , C . 2005 . Histone deacetylase inhibitors . J Med Chem , 40 : 1 – 13 .
   Google Scholar
• Steffan , J S and Bodai , L . 2001 . Histone deacetlylase inhibitors arreast polyglutamine-dependent neurodegeneration in Drosophila . Nature , 413 ( 6857 ) : 739 – 743 .
   PubMed Web of Science ®Google Scholar
• Hoshino , M , Tagawa , K Okuda , T . 2003 . Histone deacetylase activity is retained in primary neurons expressing mutant huntingtin protein . Eur J Neurochem , 87 : 257 – 267 .
   PubMed Web of Science ®Google Scholar
• Ferrante , J R , Kubilus , J R Lee , J . 2003 . Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice . J Neurosci , 23 ( 28 ) : 9418 – 9427 .
   PubMed Web of Science ®Google Scholar
• Gardian , G , Browne , S E choi , D K . 2005 . Neuroprotective effects of phenylbutyrate in teh N171-82Q transgenic mouse model of Huntington's disease . J BIol Chem , 280 : 556 – 563 .
   PubMed Web of Science ®Google Scholar
• Igarashi , S , Morita , H Bennett , K M . 2003 . Inducible PC12 cell model of Huntington's disease shows toxicity and decreased histone acetylation . Neuroreport , 14 : 565 – 568 .
   PubMed Web of Science ®Google Scholar
• Drummond , D C , Noble , C O Kirpotin , D B . 2005 . Clinical development of histone deacetylase inhibitors as anticancer agents . Annu Rev Pharmacol Toxicol , 45 : 495 – 528 .
   PubMed Web of Science ®Google Scholar
• Egorin , M J , Yuan , Z M Sentz , D L . 1999 . Plasma pharmacokinetics of butyrate after intravenous administration of sodium butyrate or oral administration of tributyrin or sodium butyrate to mice and rats . Cancer Chemother Pharmacol , 43 : 445 – 453 .
   PubMed Web of Science ®Google Scholar
• Oliveira , J M , Chen , S Ameida , S . 2006 . Mitochondrial-dependent Ca2 handling in Huntington's disease striatal cells: effect of his-tone deacetylase inhibitors . J Neurosci , 26 ( 43 ) : 11174 – 11186 .
   Google Scholar
• Butler , R and Bates , G P . 2006 . Histone deacetylase inhibitors as therapeutics for polyglutamine disorders . Nat Rev Neurosci , 7 ( 10 ) : 784 – 796 .
   PubMed Web of Science ®Google Scholar
• Saudou , F , Finkbeiner , S Devys , D . 1998 . Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions . Cell , 95 : 55 – 66 .
   PubMed Web of Science ®Google Scholar
• Waelter , S , Boeddrich , A Lurz , R . 2001 . Accumulation of mutant huntingtin fragments in aggresome-like inclusion bodies as a result of insufficient protein degradation . Mol Biol Cell , 12 : 1393 – 1407 .
   PubMed Web of Science ®Google Scholar
• Arrasate , M , Mitra , S Erik , S . 2004 . Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death . Nature , 431 : 805 – 810 .
   PubMed Web of Science ®Google Scholar